Huong Thi Xuan Hoang1,2, Alex Molassiotis3, Choi Wan Chan3, Anh Hoang Vu4, Phuc Thanh Bui5. 1. School of Nursing, The Hong Kong Polytechnic University, 11 Yuk Choi Rd, Hung Hom, Kowloon, Hong Kong. xuan-huong.hoangthi@connect.polyu.hk. 2. Faculty of Nursing, Phenikaa University, Hanoi, Vietnam. xuan-huong.hoangthi@connect.polyu.hk. 3. School of Nursing, The Hong Kong Polytechnic University, 11 Yuk Choi Rd, Hung Hom, Kowloon, Hong Kong. 4. Faculty of Nursing, Phenikaa University, Hanoi, Vietnam. 5. Vietnam-Germany University Hospital, Hanoi, Vietnam.
Abstract
PURPOSE: Current evidence for using self-acupressure to manage the cancer-related symptom cluster of insomnia, depression, and anxiety, while promising, is unknown. This study evaluated the feasibility of self-acupressure to manage this symptom cluster and to explore its potential effectiveness. METHODS: Participants were assigned randomly to three study groups, namely the true acupressure (TAP), the sham acupressure (SAP), and the enhanced standard care group (ESC). Participants in the TAP and SAP groups received a training session on acupressure and were required to practice self-acupressure at home once per day for 28 days. The duration of participant involvement was 8 weeks. Patients completed a Numerical Rating Scale (NRS) for each symptom, the Insomnia Severity Index, the Hospital Anxiety and Depression Scale, and the Functional Assessment of Cancer Therapy-General at baseline (T1), post-intervention (T2, week 4), and post follow-up (T3, week 8). RESULTS: The results indicated that the intervention had clinical significance in improving the targeted symptoms and quality of life. In the TAP group, the symptom cluster severity was significantly lower than in the other groups at T2 (p < 0.05). The insomnia severity and anxiety scores in the TAP and SAP groups were significantly lower than those in ESC at T2 and T3 (p < 0.05). CONCLUSION: The trial was feasible. The promising results of the study suggest that further testing of self-acupressure is warranted to inform its effectiveness on the targeted symptom cluster in patients with cancer. A placebo effect was evident alongside therapeutic effects. TRIAL REGISTRATION: ClinicalTrials.gov (ID: NCT03823456) on January 30th, 2019.
PURPOSE: Current evidence for using self-acupressure to manage the cancer-related symptom cluster of insomnia, depression, and anxiety, while promising, is unknown. This study evaluated the feasibility of self-acupressure to manage this symptom cluster and to explore its potential effectiveness. METHODS: Participants were assigned randomly to three study groups, namely the true acupressure (TAP), the sham acupressure (SAP), and the enhanced standard care group (ESC). Participants in the TAP and SAP groups received a training session on acupressure and were required to practice self-acupressure at home once per day for 28 days. The duration of participant involvement was 8 weeks. Patients completed a Numerical Rating Scale (NRS) for each symptom, the Insomnia Severity Index, the Hospital Anxiety and Depression Scale, and the Functional Assessment of Cancer Therapy-General at baseline (T1), post-intervention (T2, week 4), and post follow-up (T3, week 8). RESULTS: The results indicated that the intervention had clinical significance in improving the targeted symptoms and quality of life. In the TAP group, the symptom cluster severity was significantly lower than in the other groups at T2 (p < 0.05). The insomnia severity and anxiety scores in the TAP and SAP groups were significantly lower than those in ESC at T2 and T3 (p < 0.05). CONCLUSION: The trial was feasible. The promising results of the study suggest that further testing of self-acupressure is warranted to inform its effectiveness on the targeted symptom cluster in patients with cancer. A placebo effect was evident alongside therapeutic effects. TRIAL REGISTRATION: ClinicalTrials.gov (ID: NCT03823456) on January 30th, 2019.
Authors: Chao Hsing Yeh; Lung-Chang Chien; Wei-Chun Lin; Dana Howard Bovbjerg; G J van Londen Journal: Cancer Nurs Date: 2016 Sep-Oct Impact factor: 2.592
Authors: R Cerrone; L Giani; B Galbiati; G Messina; M Casiraghi; E Proserpio; M Meregalli; P Trabattoni; P Lissoni; G Gardani Journal: Minerva Med Date: 2008-12 Impact factor: 4.806
Authors: Krupali Desai; Jun J Mao; Irene Su; Angela Demichele; Qing Li; Sharon X Xie; Philip R Gehrman Journal: Support Care Cancer Date: 2012-05-15 Impact factor: 3.603
Authors: Kevin T Liou; Tim A Ahles; Sheila N Garland; Q Susan Li; Ting Bao; Yuelin Li; James C Root; Jun J Mao Journal: JNCI Cancer Spectr Date: 2019-06-07
Authors: Suzanna Maria Zick; Ananda Sen; Afton Luevano Hassett; Andrew Schrepf; Gwen Karilyn Wyatt; Susan Lynn Murphy; John Todd Arnedt; Richard Edmund Harris Journal: JNCI Cancer Spectr Date: 2019-01-16